Canada's Drug Crisis: A National Decline Masks Deepening Regional Dangers

OTTAWA, ON – June 15, 2026 – At first glance, the latest federal data on Canada's substance-related harms offers a rare glimmer of hope. A statement released today by the Council of Chief Medical Officers of Health reveals that nationally, opioid-related deaths fell by 23% in 2025, with stimulant-related deaths declining 31%. Yet, a deeper analysis of the numbers reveals a far more complex and troubling picture. While national averages trend downward, the crisis is intensifying in specific regions and evolving in dangerous new ways, demonstrating that the battle against the toxic drug supply is far from over.

Despite the national decrease, the 5,608 opioid-related deaths in 2025—an average of 15 lives lost each day—remain, in the words of the Council, "unacceptably high." These figures, while an improvement, still tower over pre-pandemic levels. The true story, however, is not in the national summary but in the stark regional disparities it conceals. The data paints a portrait of a fractured crisis, where progress in some areas is tragically offset by deepening struggles in others.

A Tale of Two Crises: Regional Realities Defy National Trends

The notion of a singular, national drug crisis is a dangerous oversimplification. While the country as a whole saw fewer deaths, several provinces and territories are grappling with a crisis that is either holding steady or worsening. In a startling reversal of the dominant narrative, jurisdictions like Saskatchewan, Manitoba, Ontario, New Brunswick, Newfoundland and Labrador, and the Northwest Territories reported higher numbers of stimulant-related deaths than opioid-related ones in 2025. This highlights a critical shift in drug use patterns and supply chains that demands localized, not monolithic, public health responses.

Perhaps most telling is the divergence between front-line emergency calls and hospital admissions. While opioid-related hospitalizations and emergency department visits saw modest national decreases of 12% and 5% respectively, Emergency Medical Service (EMS) responses to suspected overdoses increased by 9%. This paradoxical statistic is driven by staggering surges in Alberta and Saskatchewan, where EMS calls skyrocketed by 67% and 50%, respectively. This suggests that while harm reduction measures may be preventing some deaths, the sheer volume of overdose events is climbing in these provinces, placing an immense strain on first responders. The Public Health Agency of Canada attributes this surge to the increased prevalence of highly potent fentanyl analogues and other contaminants in the unregulated drug supply.

In Ontario, the situation remains dire despite a 15% decrease in opioid deaths from 2023. The province's mortality rate in 2024 was still drastically higher than before the pandemic, with fentanyl implicated in over 83% of opioid toxicity deaths. The data underscores that national victories are cold comfort for communities where the crisis continues to rage with unabated fury.

The Benzodiazepine Factor: A New Wave of Complexity

Compounding the regional challenges is a perilous evolution in the chemical makeup of the street drug supply. An alarming analysis released alongside the mortality data reveals that benzodiazepine involvement in both the unregulated drug supply and resulting deaths has increased threefold between 2018 and 2024. These sedatives, often prescribed for anxiety, have become a pervasive and deadly adulterant. Their contribution to opioid toxicity deaths soared from 8% in 2018 to a staggering 34% in 2024.

This polysubstance cocktail dramatically increases the risk of fatal overdose. Benzodiazepines, or "benzos," compound the respiratory depression caused by opioids, creating a synergistic effect that is far more difficult to treat. Critically, benzodiazepines are not opioids and do not respond to naloxone, the life-saving overdose reversal drug. First responders now face scenarios where a victim revived from an opioid overdose remains unconscious and in respiratory distress due to the effects of co-ingested benzodiazepines, requiring more complex medical intervention.

This development poses a significant challenge to established harm reduction technologies and protocols. It underscores the vital importance of drug checking services—technological platforms that allow individuals to anonymously test the composition of their drugs. Services in Toronto and British Columbia have proven effective at identifying unexpected substances like benzodiazepines, allowing users to make more informed decisions. However, the limited geographic reach of these services means they are not yet a primary driver of national outcomes, highlighting a critical gap in public health infrastructure that must be addressed to combat this evolving threat.

The Human Toll and a Resilient Response

Behind every statistic is a story of profound loss. As Canada's Chief Public Health Officer, Dr. Joss Reimer, emphasized, "behind every number, every statistic, is a person. Every overdose is a tragedy, causing profound and lasting trauma to families, to friends and entire communities." The government continues to deploy resources, including over $70 million from the Emergency Treatment Fund and $75 million from the Substance and Addictions Program in the 2025-26 fiscal year to support community-led initiatives.

In the face of this enduring crisis, a powerful grassroots response has emerged. Organizations like Moms Stop the Harm (MSTH) and Families for Addiction Recovery (FAR) have become lifelines for those impacted. These networks, built by families who have experienced the sharp pain of substance use and loss, provide peer support, advocate for evidence-based policy, and fight the stigma that so often isolates affected families. Through programs like MSTH's "Holding Hope" for families with loved ones currently using substances and "Healing Hearts" for the bereaved, they are building communities of care where statistics become names, and grief is met with understanding.

While the national decline in deaths is a testament to the tireless work of harm reduction advocates and the effectiveness of measures like widespread naloxone distribution, the 2025 data serves as a stark warning. The crisis is not abating; it is changing. It is becoming more regionalized, more chemically complex, and more entrenched in communities across the country, demanding a response that is equally nimble, innovative, and deeply compassionate.